Clinical Trial

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

Name: A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome — clinical trial record (NCT07503444)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).

Protocol Amendment History 1 change

notable Trial sites expanded: 5 -> 9 locations 2026-06-27

Trial Details

NCT Number	NCT07503444
Lead Sponsor	UCB BIOSCIENCES, Inc.
Conditions	Rett Syndrome
Enrollment	200 participants
Start Date	2026-06-30
Primary Completion	2028-08-01 (estimated)
Study Completion	2030-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-10